Form 4: Alkermes Director Nancy Lurker Reports Acquisition of Stock Options and Restricted Stock Units

Director Nancy Lurker reports acquisition of stock options and restricted stock units in Alkermes plc.

Summary

• Nancy Lurker, a director of Alkermes plc, filed a Form 4 with the SEC on April 12, 2024.
• The report details the acquisition of derivative securities, specifically non-qualified stock options and restricted stock units.
• On April 11, 2024, Lurker acquired 4,833 non-qualified stock options exercisable at $24.99, vesting fully on April 11, 2025, and expiring on April 11, 2034.
• She also acquired 22,103 non-qualified stock options exercisable at $24.99, vesting in three equal annual installments commencing on April 11, 2025, and expiring on April 11, 2034.
• Additionally, Lurker acquired 2,323 restricted stock units that vest in full on April 11, 2025.
• She also acquired 11,255 restricted stock units that vest in three equal annual installments commencing on April 11, 2025.
• Following these transactions, Lurker directly owns 4,833 and 22,103 non-qualified stock options and 2,323 and 11,255 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and restricted stock units by a director is generally a positive sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options and restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules for the stock options and restricted stock units extend into the future.

Industry Context

Director stock acquisitions are common and are generally viewed as a positive sign, indicating the director's belief in the company's future prospects. The vesting schedules are typical for executive compensation packages.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a standard component of executive compensation packages in the pharmaceutical industry, used to align management's interests with those of shareholders.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation strategies for their executives.
• The vesting schedules described are fairly standard, with many companies using three-year vesting periods for stock options and restricted stock units.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a director can positively influence shareholder sentiment.

Key Dates